AVR
Anteris Technologies Global Corp.
🇦🇺 ASX
📈 HIGH PRICE GROWTH
🩺 HEALTH CARE
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
+ 33.79%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
4
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Anteris Technologies Ltd. is a structural heart company, which engages in research, develops, commercializes, and distributes medical technologies and devices. The company is headquartered in Toowong, Queensland. The company went IPO on 2004-03-24. The firm is engaged in designing, developing, and commercializing medical devices. The Company’s lead product, DurAVR, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR THV is made using ADAPT tissue, its patented anti-calcification tissue technology. DurAVR THV is a novel first-in-class biomimetic valve made from a single piece of native-shaped tissue. The company is designed to mimic the performance of a pre-disease human aortic valve. Its balloon expandable ComASUR Delivery System provides controlled deployment and accurate placement of the DurAVR THV valve, designed to achieve precise alignment with the heart’s native commissures to achieve ideal valve positioning.
📈 Performance
Price History
+19.57%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$11.00
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in AVR
4
📊 Total Capital Earnings
$263.39
🔃 Average investment frequency
64 weeks
💵 Average investment amount
$1,176
⏰ Last time a customer invested in AVR
267 days
AVR investor breakdown
💵 Income of investors
More than 200k
150k - 200k
25%
100k - 150k
25%
50k - 100k
50%
Less than 50k
👶 Age of investors
18 - 25
26 - 34
50%
35 - 90
50%
🙋 Legal gender of investors
Female
75%
Male
25%
Pearlers who invest in AVR also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
8.49%
📊 Share price
$96.95 AUD
🇦🇺 AUSTRALIA
⛳️ DIVERSIFIED
🧱 MATERIALS
📈 HIGH PRICE GROWTH
💸 FINANCIALS
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
17.63%
📊 Share price
$134.81 AUD
🤖 TECHNOLOGY
🌏 GLOBAL
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
🙌 Performance (5Yr p.a)
2519.76%
📊 Share price
$10.54 AUD
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
🙌 Performance (5Yr p.a)
14.44%
📊 Share price
$0.03 AUD
🧬 BIOTECHNOLOGY
📈 HIGH PRICE GROWTH
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
22.94%
📊 Share price
$59.22 AUD
🇺🇸 UNITED STATES
📈 HIGH PRICE GROWTH
Want more shares? Try these...
